PepGen reported positive Phase 2 results from the 10mg/kg cohort in its FREEDOM2-DM1 trial, marking a clinical milestone for its myotonic dystrophy type 1 candi

BWB News TV • 2026-11-10 12:22 UTC • By Billy Odell Tucker-Robinson

PepGen reported positive Phase 2 results from the 10mg/kg cohort in its FREEDOM2-DM1 trial, marking a clinical milestone for its myotonic dystrophy type 1 candidate and progress toward a potential treatment.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly